Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Dengue virus (DENV) is a major global health challenge, causing over 7.6 million reported cases in 2024. Neutralizing monoclonal antibodies (NmAbs) have emerged as promising therapeutics to address the limitations of vaccines and lack of antivirals, but their development is complicated by viral diversity, "breathing" dynamics, and antibody-dependent enhancement (ADE).
Objectives: This scoping review aimed to map and synthesize evidence on NmAbs targeting DENV, summarizing their epitopes, mechanisms, serotype coverage, neutralization potency, and development status.
Methods: We searched PubMed (to June 2025) for studies characterizing NmAbs with in vitro or in vivo DENV neutralization. Inclusion required primary data on neutralizing activity. Data extraction included antibody origin, epitope, potency, ADE risk, and clinical progress.
Results: Fifty-six studies were included, covering more than 30 NmAbs. Fusion loop-directed antibodies (e.g., 3G9, E53) display broad reactivity but frequently mediate ADE unless Fc-modified. E-dimer epitope (EDE) antibodies (A11, B7, C8, C10) recognize quaternary epitopes with high in vitro potency, though evidence for in vivo protection and ADE avoidance remains limited. Domain III-directed antibodies (e.g., m366.6, 1C19) show serotype-spanning activity, while others such as 2D22 or DENV-290 exhibit potent type-specific neutralization. Several candidates demonstrate efficacy in animal models, and two human antibodies, VIS513 and AV-1, have advanced to clinical evaluation, with VIS513 completing Phase 1 trials.
Conclusions: NmAbs offer a promising adjunct to dengue care but require careful epitope selection and Fc engineering to balance potency and safety. Continued preclinical and clinical evaluation is essential to advance these candidates toward therapeutic use.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.virol.2025.110677 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Inhibitory activities of monoclonal antibodies against clumping factor A.
mBio
September 2025
Department of Microbiology, Howard Taylor Ricketts Laboratory, The University of Chicago, Lemont, Illinois, USA.
infection is a frequent cause of sepsis in humans, a disease associated with high mortality and without specific intervention. Clumping factor A (ClfA) displayed on the bacterial surface plays a key role in promoting replication during invasive disease. Decades of research have pointed to a wide array of ligands engaged by ClfA.
View Article and Find Full Text PDFEngineering a Coiled-Coil Protein for DARPin Presentation as a Potent SARS-CoV-2 Therapeutic.
Biomacromolecules
September 2025
School of Chemical and Biomolecular Engineering, Georgia Institute of Technology, 950 Atlantic Dr NW, Atlanta, Georgia 30332, United States.
The COVID-19 pandemic has demonstrated the need for rapid, flexible, and readily adaptable treatment options for future pandemic preparedness. Due to the speed at which viruses like SARS-CoV-2 mutate, the customary approach of using highly specific monoclonal antibodies as neutralization therapies is challenging, given their size, production complexity, and cost. Here, we leveraged rational protein design to create fusion proteins from small, antibody-mimetic proteins, Designed Ankyrin Repeat Proteins (DARPins) and a self-assembling hexameric coiled coil (CC-HEX).
View Article and Find Full Text PDFA Porcine Monoclonal Antibody Targeting a Conserved GP4 Epitope Protects against In Vivo Infection via the Induction of Broad-Spectrum PRRSV Neutralization.
Adv Sci (Weinh)
September 2025
College of Veterinary Medicine, Northwest A&F University, Yangling, 712100, China.
Porcine reproductive and respiratory syndrome virus (PRRSV) imposes substantial economic losses on global swine production. While modified live vaccines remain the primary prevention tool, their efficacy is compromised by the genetic variability of PRRSV. This study developed a broadly neutralizing monoclonal antibody (mAb) that targets a conserved viral epitope as an alternative therapeutic strategy.
View Article and Find Full Text PDFHIV-1 bNAb Vaccinal Effect - An Underachieving Goal?
Curr HIV Res
August 2025
U.S. Mil-itary HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
Reports of HIV-1-specific broadly neutralizing monoclonal antibodies (bNAbs) medi-ating a potential 'vaccinal effect' implicate passively transferred bNAbs in promoting endoge-nous anti-HIV-1 immune responses. To date, three clinical trials have reported either increased anti-HIV-1 neutralizing antibodies or T cell responses following bNAb administration to people living with HIV. Despite strong enthusiasm for this hypothesis, motivated in large part by its potential application to HIV-1 therapeutic strategies, the mechanism(s) underlying a vaccinal ef-fect remain unclear.
View Article and Find Full Text PDFNeutralizing monoclonal antibodies against dengue virus: a scoping review of preclinical and clinical development.
Virology
September 2025
Department of Medicine, Democritus University of Thrace, Alexandroupolis, Evros, Greece.
Background: Dengue virus (DENV) is a major global health challenge, causing over 7.6 million reported cases in 2024. Neutralizing monoclonal antibodies (NmAbs) have emerged as promising therapeutics to address the limitations of vaccines and lack of antivirals, but their development is complicated by viral diversity, "breathing" dynamics, and antibody-dependent enhancement (ADE).
View Article and Find Full Text PDF